Marija Tadin-Strapps
Discovery Network, Discovery Early Development, Pfizer Research & Development Head Pfizer
Marija Tadin-Strapps is Head of Discovery Network, Pfizer R&D. In this role, Marija is responsible for driving the development and execution of the external discovery strategy to maximize portfolio growth through establishing key external partnerships.
A scientific leader with 20 years of experience in organizations ranging from start up to large pharmaceutical companies, Marija most recently held the position of Head of Target Sciences in the Emerging Science and Innovation (ES&I) organization at Pfizer. Prior to joining Pfizer in 2021, Marija held leadership positions at SQZ Biotechnologies, Omega Therapeutics and Merck (MSD) providing her experience across different modalities, including RNA therapeutics, epigenetic gene modulation, cell therapy, and the use of genetics and functional genomics for new target identification and validation, biomarker discovery and translational research across multiple disease areas.
Marija earned her B.A. degree in Biology with honors from Goucher College and her Master and Doctorate degrees in Genetics and Development from Columbia University. She has authored multiple peer-reviewed publications on the use of chemically modified siRNAs and the use of human genetics for new target discovery.
Seminars
What is this session?
- With a high concentration of relevant companies in one place, the pharma icebreaker tables offer a guaranteed opportunity for face-to-face interactions. Whether you’re connected on the One-on-One Partnering™ portal or not, this is a formal opportunity to introduce yourself and your organization
How is this organized?
- Two weeks out from the conference, pharma will review attending biotech and biotech will review attending pharma, with both making selections to meet with companies they haven’t scheduled meetings with yet
- With these selections, we will build a schedule of company rotations through each pharma’s table, across 90 minutes
- This ensures you meet face-to-face with priority companies and can introduce yourself to new pharma contacts early in the event. Don’t miss out on this unique chance to expand your network and forge valuable connections!
- Understanding why pharma would invest. What gap are the innovative technologies filling and what is the sentiment for dealmaking right now?
- What do pharma need to see? Sharing direction into what is expected when approaching pharma as a partner
- Insights into how biotech can differentiate in crowded markets
